<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8709751</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5899</journal-id>
<journal-id journal-id-type="nlm-ta">Mol Cell Probes</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Cell. Probes</journal-id>
<journal-title-group>
<journal-title>Molecular and cellular probes</journal-title>
</journal-title-group>
<issn pub-type="ppub">0890-8508</issn>
<issn pub-type="epub">1096-1194</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29307697</article-id>
<article-id pub-id-type="pmc">6033695</article-id>
<article-id pub-id-type="doi">10.1016/j.mcp.2018.01.001</article-id>
<article-id pub-id-type="manuscript">NIHMS933637</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Modeling Rare Diseases with Induced Pluripotent Stem Cell Technology</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Anderson</surname>
<given-names>Ruthellen H.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Francis</surname>
<given-names>Kevin R.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Cellular Therapies and Stem Cell Biology Group, Sanford Research, Sioux Falls, SD, USA</aff>
<aff id="A2">
<label>2</label>Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, USA</aff>
<aff id="A3">
<label>3</label>Department of Pediatrics, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, USA</aff>
<author-notes>
<corresp id="FN1"><bold>Corresponding author</bold>: Kevin R. Francis, PhD, Cellular Therapies and Stem Cell Biology Group, 2301 E 60<sup>th</sup> Street North, Sanford Research, Sioux Falls, SD, USA. Telephone: +1 605 312 6422; Fax: +1 605 328 0401; <email>kevin.francis@sanfordhealth.org</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>17</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>05</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>8</month>
<year>2019</year>
</pub-date>
<volume>40</volume>
<fpage>52</fpage>
<lpage>59</lpage>
<!--elocation-id from pubmed: 10.1016/j.mcp.2018.01.001-->
<abstract>
<p id="P1">Rare diseases, in totality, affect a significant proportion of the population and represent an unmet medical need facing the scientific community. However, the treatment of individuals affected by rare diseases is hampered by poorly understood mechanisms preventing the development of viable therapeutics. The discovery and application of cellular reprogramming to create novel induced pluripotent stem cell models of rare diseases has revolutionized the rare disease community. Through developmental and functional analysis of differentiated cell types, these stem cell models carrying patient-specific mutations have become an invaluable tool for rare disease research. In this review article, we discuss the reprogramming of samples from individuals affected with rare diseases to induced pluripotent stem cells, current and future applications for this technology, and how integration of genome editing to rare disease research will help to improve our understanding of disease pathogenesis and lead to patient therapies.</p>
</abstract>
<kwd-group>
<kwd>Rare disease</kwd>
<kwd>induced pluripotent</kwd>
<kwd>pluripotency</kwd>
<kwd>iPSC</kwd>
<kwd>CRISPR</kwd>
<kwd>disease modeling</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>